BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Lifetime of Protection Against COVID-19 May Be Possible with mRNA Vaccines

  A new study published in Nature offers good news for those who recovered from COVID-19 and were then vaccinated with a mRNA vaccine – a booster may not be needed.

  June 29, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Biopharmas Ink Strategic Partnerships for Research, Treating Major Diseases

  Three partnerships were signed today between biopharmaceutical and therapeutics companies in a bid to develop treatment for major diseases with high mortality rates.

  June 29, 2021

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Sanofi Makes Big Move Into mRNA Vaccine Space

  The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.

  June 29, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie’s Rinvoq Shows Promise as Maintenance Drug for Ulcerative Colitis Treatment

  Rinvoq shows promising results for Ulcerative Colitis Treatment. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.

  June 29, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  House Seeks to Increase Scientific Competitiveness with New Bipartisan Bill

  On Monday, the House passed a bipartisan bill designed to reportedly boost scientific research and increase the scientific competitiveness of the U.S. to that of China.

  June 29, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Drug Development

  Orphazyme Mulls Restructure to Focus On Potential Niemann-Pick Disease Type C Treatment

  Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.

  June 29, 2021

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  Gilead Sciences Seeks Approval for Twice-Annual HIV-1 Medication

  If approved, lenacapavir would be offered to HIV patients who have been heavily treated for the disease and have multi-drug-resistant HIV.

  June 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Novartis Takes Roche to Court Over $210 Million Licensing Fees

  The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.

  June 29, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Amgen to Break Ground in Ohio with $365 Million “Smart” Facility

  Major players in the biotech industry are targeting Ohio for their new facilities, including Amgen, which recently dropped $365 million on a “digitally advanced” smart facility just 15 miles outside the state’s capital.

  June 29, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  Exelixis Shares Dive After Announcing News of Carcinoma Survival Data

  The two companies studying the regimen for HCC, Exelixis and Ipsen, suggest the probability of reaching significance at the final analysis is low.

  June 29, 2021

   · 

  2 min read

   · 

  Brandon May